1 **A multidimensional analysis reveals distinct immune phenotypes and the**

2 **composition of immune aggregates in pediatric acute myeloid leukemia**

- 3 Joost B. Koedijk^{1,2}, Inge van der Werf^{1,3}, Livius Penter^{4,5,6,7}, Marijn A. Vermeulen¹, Farnaz
- 4 Barneh¹, Alicia Perzolli^{1,2}, Joyce I. Meesters-Ensing¹, Dennis S. Metselaar^{1,8,9}, Thanasis
- 5 Margaritis¹, Marta Fiocco^{1,10,11}, Hester A. de Groot-Kruseman¹, Rubina Moeniralam¹, Kristina
- 6 Bang Christensen¹², Billie Porter¹³, Kathleen Pfaff¹³, Jacqueline S. Garcia^{4,6}, Scott J. Rodig¹⁵,
- 7 Catherine J. Wu^{4,5,6,14}, Henrik Hasle¹⁶, Stefan Nierkens^{1,17}, Mirjam E. Belderbos¹, C. Michel
- 8 Zwaan^{1,2#}, Olaf Heidenreich^{1,18#*}
- 9 ¹ Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
- ² Department of Pediatric Oncology, Erasmus MC/Sophia Children's Hospital, 3015 GD
- 11 Rotterdam, The Netherlands.
- 12 ³ Oncode Institute, 3521 AL, Utrecht, The Netherlands
- 13 ⁴ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
- 14 ⁵ Broad Institute of Massachusetts Institute of Technology and Harvard University,
- 15 Cambridge, MA, USA
- 16 ⁶ Harvard Medical School, Boston, MA, USA
- 17 ⁷ Department of Hematology, Oncology, and Tumorimmunology, Campus Virchow Klinikum,
- 18 Berlin, Charité Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität
- 19 zu Berlin, Berlin, Germany
- 20 ⁸ Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany
- 21 ⁹ Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and
- 22 German Consortium (DKTK), Im Neuenheimer Feld 280, Heidelberg, Germany
- 23 ¹⁰ Mathematical Institute, Leiden University, Leiden, The Netherlands
- 24 ¹¹ Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The
- 25 Netherlands.
- 26 ¹² Department of Pathology, Aarhus University Hospital, Aarhus, Denmark
- 27 ¹³ Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
- 28 ¹⁴ Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA
- 29 ¹⁵ Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA
- 30 ¹⁶ Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark
- 31 ¹⁷ Center for Translational Immunology, University Medical Center Utrecht, 3584 CX Utrecht,
- 32 The Netherlands.
- 33 ¹⁸Wolfson Childhood Cancer Research Centre, Newcastle University, Newcastle upon Tyne
- 34 NE1 7RU, UK.
- 35 **#Equal contribution**

- 36 *Corresponding author and lead contact: Olaf Heidenreich, Princess Máxima Center for
- 37 Pediatric Oncology, 3584 CS Utrecht, The Netherlands. Phone: 088-9727272; E-mail:
- 38 o.t.heidenreich@prinsesmaximacentrum.nl
- 39 **Running title:** The spatial organization of immunity in pediatric AML
- 40 **Figures/Tables:** 5 Main Figures, 6 Supplementary Figures, 6 Supplementary Tables.
- 41 **Word count main text:** 4640 **Word count abstract:** 203 **References:** 62
- 42

43 **Competing interests:**

- 44 J.S.G. reports serving on steering committee and receiving personal fees from AbbVie,
- 45 Genentech, and Servier and institutional research funds from AbbVie, Genentech, Pfizer,
- 46 and AstraZeneca.
- 47 S.R. receives research support from Bristol-Myers-Squibb and KITE/Gilead, and is a
- 48 member of the SAB of Immunitas Therapeutics.
- 49 C.J.W. holds equity in BioNTech, Inc and receives research support from Pharmacyclics.
- 50 C.M.Z. receives institutional research support from Pfizer, Abbvie, Takeda, Jazz, Kura,
- 51 Gilead, and Daiichi Sankyo, provides consultancy services for Kura, Bristol-Myers-Squibb,
- 52 Novartis, Gilead, Incyte, and Syndax, and serves on advisory committees for Novartis,
- 53 Sanofi, and Incyte.
- 54 O.H. receives institutional research support from Syndax and Roche.
- 55 The remaining authors declare no competing financial interests.
- 56

58 **Abstract**

59 Because of the low mutational burden and consequently, fewer potential neoantigens, 60 children with acute myeloid leukemia (AML) are thought to have a T cell-depleted or 'cold' 61 tumor microenvironment and may have a low likelihood of response to T cell-directed 62 immunotherapies. Understanding the composition, phenotype, and spatial organization of T 63 cells and other microenvironmental populations in the pediatric AML bone marrow (BM) is 64 essential for informing future immunotherapeutic trials about targetable immune-evasion 65 mechanisms specific to pediatric AML. Here, we conducted a multidimensional analysis of 66 the tumor immune microenvironment in pediatric AML and non-leukemic controls. We 67 demonstrated that nearly one-third of pediatric AML cases has an immune-infiltrated BM, 68 which is characterized by a decreased ratio of M2- to M1-like macrophages. Furthermore, 69 we detected the presence of large T cell networks, both with and without colocalizing B cells, 70 in the BM and dissected the cellular composition of T- and B cell-rich aggregates using 71 spatial transcriptomics. These analyses revealed that these aggregates are hotspots of CD8⁺ 72 T cells, memory B cells, plasma cells and/or plasmablasts, and M1-like macrophages. 73 Collectively, our study provides a multidimensional characterization of the BM immune 74 microenvironment in pediatric AML and indicates starting points for further investigations into 75 immunomodulatory mechanisms in this devastating disease.

76

77 **Keywords:** spatial transcriptomics, trephine, tertiary lymphoid structures, ectopic T cell 78 networks, hematological malignancies.

80 **Introduction**

81 The abundance and phenotype of intratumoral T cells are crucial for the effectiveness of T 82 cell-directed immunotherapies such as immune checkpoint inhibitors (ICIs) and bispecific T 83 cell-engagers¹⁻⁴. Because of the low mutational burden and consequently, fewer potential 84 neoantigens, children with acute myeloid leukemia (AML) are thought to have a T cell-85 depleted or 'cold' tumor microenvironment and therefore may have a low likelihood of 86 response to ICIs and bispecific T cell-engagers⁵⁻⁸. Although clinical trials in adult AML 87 patients treated with ICIs and bispecific T cell-engagers, whether as mono- or combination 88 therapy, have largely been unsuccessful, a small subset of patients showed exceptional 89 responses^{4, 9-15}. This suggests that there may be specific subgroups that could benefit from 90 these T cell-directed immunotherapies. To pave the way for successful ICI- and bispecific T 91 cell-engager immunotherapies in both adult and pediatric AML, a better understanding of the 92 heterogenous landscape of bone marrow (BM)-infiltrating T cells and the surrounding tumor 93 microenvironment is needed. While recent studies have provided insights on this matter in 94 adult AML, such as the identification of a relatively low presence of exhausted $CDS⁺ T$ cells 95 in the tumor microenvironment compared to cancers that respond well to ICIs^{16, 17}, there is a 96 paucity of data on the BM immune microenvironment in pediatric $AML^{11, 18-20}$. In addition to 97 the need for a quantitative and qualitative assessment of the pediatric AML BM immune 98 microenvironment, emerging research in solid cancers has shown that the spatial 99 organization of the immune response is highly relevant for ICI efficacy²¹. For instance, 100 'excluded' tumors, where the immune response cannot invade the tumor bed, show poor 101 responses to $|Cl^{22}$. Furthermore, the presence of intratumoral immune aggregates, such as 102 tertiary lymphoid structures (TLS), is associated with improved ICI responses in many solid 103 cancers²³⁻²⁸. Despite its potential importance, the spatial organization of the immune 104 response in hematological cancers remains understudied. Therefore, we generated a 105 multidimensional view of the tumor immune microenvironment in treatment-naïve *de novo* 106 pediatric AML, to inform future immunotherapeutic trials about potentially targetable immune-107 evasion mechanisms specific to this patient population. We identified distinct BM immune 108 phenotypes and dissected the composition of immune aggregates in the BM of pediatric 109 AML, which encourage further investigations into immunomodulatory mechanisms in this 110 devastating disease.

111 **Materials/Subjects and Methods**

112 **Ethical regulation**

113 This study complies with all relevant ethical regulations and was approved by the 114 Institutional Review Boards of the Princess Máxima Center for Pediatric Oncology

115 (PMCLAB2021.207 & PMCLAB2021.238), the Scientific Committee of the Dutch Nationwide 116 Pathology Databank (PALGA: $Izv2021-82$)²⁹ and at participating sites of the ETCTN/CTEP 117 10026 study $12, 13$. All patients treated at the Princess Máxima Center, Aarhus University 118 Hospital, and Dana-Farber Cancer Institute provided written consent for banking and 119 research use of these specimens, according to the Declaration of Helsinki.

120 **Human patient samples**

121 FFPE BM biopsies taken from the crista of children with treatment-naïve *de novo* AML and 122 non-leukemic controls (Supplementary Methods) were obtained from the Princess Máxima 123 Center Biobank (n=15), biobanks of 10 other Dutch hospitals (n=28; mediated by the Dutch 124 National Tissue Portal) and the biobank of Aarhus University Hospital (n=29). BM biopsies of 125 adult AML cases treated on the ETCTN/CTEP 10026 study (n=6) were collected at Dana-126 Farber Cancer Institute^{13, 17}. Details on other pediatric and adult AML datasets, 127 immunohistochemistry/immunofluorescence, digital image analysis, spatial transcriptomics, 128 and immune-related gene expression profiling are provided in the Supplementary Methods.

129 **Statistical analyses**

130 Statistical analyses were performed with GraphPad Prism V.9.3.0 (GraphPad Software, LA 131 Jolla, CA, USA). Details on the various statistical tests used are provided in the 132 Supplementary Methods. For spatial transcriptomics data, *P*<0.01 was considered 133 statistically significant to correct for measuring multiple regions from the same biopsy. For all 134 other comparisons, *P*<0.05 was considered statistically significant.

135 **Results**

136 **A subset of pediatric AML patients has high T cell infiltration in the bone marrow**

137 To determine whether the BM microenvironment in pediatric AML is characterized by high 138 ('hot') or low ('cold') T cell infiltration, we performed immunohistochemistry (IHC) with 139 antibodies against CD3 and CD8 on 82 formalin-fixed and paraffin-embedded (FFPE) BM 140 biopsies from pediatric patients with treatment-naïve *de novo* AML (n=72), and age- and 141 sex-matched non-leukemic individuals (n=10; **Fig. 1A**; representative images shown in **Fig.** 142 **1B-C;** collectively referred to as 'primary study cohort'). Patient characteristics are depicted 143 in **Table S1**. We found a trend towards a decreased abundance of the number of T cells and 144 a significant decrease in CD8⁺ T cells in pediatric AML cases in comparison to non-leukemic 145 controls (*P*=0.11 and *P*=0.011, respectively; **Fig. 1D-E**), similar to other observations in adult 146 and pediatric AML^{20, 31, 32}. The T- and CD8⁺ T cell infiltration ranged from 55 to 9832 147 cells/mm² between individual pediatric AML cases, with a subset showing high T- and CD8⁺

148 T cell infiltration in the BM (above median of non-leukemic controls; n=22 and n=18, 149 respectively; **Fig. 1D-E**).

150 We next explored whether this heterogeneity in T cell infiltration reflected inherent 151 differences in disease biology. Notably, eleven out of nineteen patients with *KMT2A*-152 rearranged AML (58%) and five out of eight patients with complex karyotype AML (63%) had 153 high BM T cell infiltration (**Fig. 1F**). However, substantial heterogeneity in T cell infiltration 154 was also present within both the *KMT2A*-rearranged and complex karyotype AML groups 155 (**Fig. 1F-G**). Thus, both high and low levels of BM T cell infiltration were noted among 156 *KMT2A*-rearranged and complex karyotype AML patients. Most cases in the other 157 cytogenetic subgroups had low overall T- and CD8⁺ T cell infiltration (Fig. 1F-G). Specifically, 158 twelve out of thirteen cases (92%) with normal karyotype AML had low total T- and CDB^+T 159 cell infiltration. Among these thirteen cases, nine (69%) had both low T cell infiltration and a 160 *FLT3*-ITD and/or *NPM1* mutation (**Table S1**), which have been associated with low T- and 161 NK cell infiltration in adult $AML³³$. Using diagnostic flow cytometry data of an independent 162 cohort of 20 pediatric cases with normal karyotype AML (n=12 wildtype, n=8 *FLT3*-ITD 163 and/or *NPM1* mutation), we confirmed this association (*P*=0.013; **Fig. S1A**).

164 Given the relatively small number of samples in some cytogenetic subgroups, we 165 also reanalyzed a large bulk RNA-sequencing dataset of treatment-naïve pediatric AML BM 166 aspirates (TARGET-AML cohort, n=159 patients; Fig. 1H)³⁴. Using the immune 167 deconvolution tool CIBERSORT $x^{17, 35, 36}$, we estimated the absolute abundance scores of Tand CD8⁺ 168 T cells, which ranged from 0.15 to 5.15 and 0 to 1.43, respectively (**Fig. 1H-J**). We 169 categorized patients into overall T- and $CDB⁺$ T cell-high and -low groups based on the 170 median estimated BM T- and CD8⁺ T cell abundance in four non-leukemic pediatric controls 171 (BM bulk RNA-sequencing data 37). The TARGET-AML cohort showed substantial 172 heterogeneity in overall T- and CD8⁺ T cell levels across all cytogenetic subgroups, with only 173 nine out of 27 *KMT2A*-rearranged AML cases (33%) having high T cell infiltration (**Fig. 1I-J**). 174 Consequently, we hypothesized that specific *KMT2A*-rearrangements may be associated 175 with different levels of T cell infiltration in the BM. We therefore compared the levels of T-176 and CD8⁺ T cells among cases with *KMT2A*-rearrangements with at least three samples per 177 group (TARGET-AML cohort). This analysis suggested a lower abundance of CD8⁺ T cells in 178 *KMT2A*::*ELL* AML compared to *KMT2A*::*MLLT3* AML (*P=*0.044; **Fig. S1B-C**), although the 179 small sample size precluded firm conclusions. Among cases with complex karyotype AML, 180 thirteen out of 24 cases (54%) had high T cell infiltration (**Figure 1I**). However, we were not 181 able to identify any commonalities between those with high or low T cell infiltration. Other 182 clinical factors including the abundance of leukemic blasts and AML differentiation stage 183 showed no or only marginal correlation with T- and CD8⁺ T cell infiltration (**Fig. S1D-K)**.

184 To further characterize the immune profiles of pediatric AML cases with a high 185 abundance of T cells in the BM, we categorized AML cases in the primary study cohort into 186 two groups using the non-leukemic controls' median $CD3⁺$ T cell abundance as the cut-off 187 value (1133 cells/mm²; Fig. 2A). Focused IHC analyses of CD20 expression showed that 188 patients in the CD3⁺ T cell-high group also had a significantly higher abundance of CD20⁺ B 189 cells in comparison to the CD3⁺ T cell-low group (*P*<0.001; **Fig. 2B**). Accordingly, we termed 190 the two groups 'immune-infiltrated' and 'immune-depleted' (n=22 and n=50, respectively). 191 We subsequently investigated whether these groups demonstrated differences in clinical 192 outcomes upon standard chemotherapy treatment (Supplementary Methods), as seen in 193 many other cancer types¹. In our cohort, we did not detect differences in overall survival 194 (OS) between the immune-infiltrated and immune-depleted group (**Fig. S2A**). To increase 195 statistical power, we repeated the analysis in the TARGET-AML cohort. Again, we did not 196 detect differences in OS between the immune-infiltrated (CD3⁺ T cell-high, n=66) and 197 immune-depleted (CD3⁺ T cell-low, n=93) groups (Fig. S2B), together suggesting that the 198 extent of T cell infiltration in the BM at diagnosis is not critical for patient survival in pediatric 199 AML cases treated with standard chemotherapy regimens. Taken together, we identified 200 wide heterogeneity in T cell infiltration in the BM of pediatric AML with nearly one-third of 201 cases (31%) showing notably high T cell infiltration. In addition, our findings suggest that 202 specific genetic alterations may be linked to the extent of T cell infiltration in the BM of 203 pediatric AML, although the exact underlying mechanisms remain to be unraveled^{38, 39}.

204 **The ratio of M2- to M1-like macrophages is linked to the extent of T cell infiltration in** 205 **the pediatric AML bone marrow**

206 To elucidate mechanisms driving high- and low immune infiltration in the BM of pediatric 207 AML, we examined the expression of immune-related genes in a cytogenetically 208 representative subset of immune-infiltrated (n=6) and immune-depleted cases (n=17) using 209 the NanoString PanCancer IO 360^{TM} panel (Fig. 2A). Using differential gene expression 210 analysis, we identified genes related to T- and/or NK cells to be significantly upregulated in 211 immune-infiltrated compared to immune-depleted pediatric AML (**Fig. 2C**), confirming our 212 categorization of cases into these two groups. Regarding factors that either promote or 213 restrict T cell infiltration, we found that immune-infiltrated cases demonstrated significantly 214 higher expression of genes related to T cell-attracting chemokines (*CXCL9*, *CXCL10*), and 215 their corresponding receptor (*CXCR3*; **Fig. 2C**). In line with this, pathway analysis using the 216 GO biological processes and WikiPathways gene sets indicated that immune-infiltrated 217 cases were enriched in T cell migration and chemokine signaling, suggesting that immune-218 depleted cases lack signals that attract T cells to the BM (**Fig. 2D**; full list of pathways in 219 **Table S2**). In solid cancers, macrophages have been described as key players in attracting

220 \top cells⁴⁰. Specifically, pro-inflammatory M1-like macrophages are known to be a primary 221 source of T cell-attracting chemokines, while anti-inflammatory M2-like macrophages restrict 222 \top cell infiltration into the tumor^{40, 41}. Previously, a gene expression-based score that reflects 223 the ratio between M2- and M1-like macrophages (a score > 0 indicates M2-predominance, 224 while a score < 0 indicates M1-predominance; collectively termed M2-predominance score) 225 has been developed for five cancer types including AML^{42} . We applied this score to our 226 cohort and found that the M2-predominance score was negatively correlated with the BM T-227 and CD8⁺ T cell abundance ($r = -0.75$ [95% CI: -0.89 to -0.48], *P*<0.001; $r = -0.50$ [95% CI: -228 0.76 to -0.12], *P*=0.014, respectively; **Fig. 2E,F** and **Fig. S2C**). Concordantly, we identified a 229 significantly decreased M2-predominance score in immune-infiltrated compared to immune-230 depleted cases (*P*=0.001; **Fig. 2G**). Likewise, in the TARGET-AML cohort, we detected a 231 (subtle) negative correlation between the M2-predominance score and the T - and CDB^+T 232 cell abundance in the BM (*r*=-0.25 [95% CI: -0.39 to -0.10], *P*=0.002; *r=*-0.20 [95% CI: -0.35 233 to -0.05], *P*=0.011, respectively; **Fig. 2H** and **Fig. S2D**), and a significantly decreased M2- 234 predominance score in the immune-infiltrated compared to the immune-depleted group 235 (*P*<0.001.; **Fig. 2I**). Altogether, our data suggest that the M2-:M1-like macrophage ratio is 236 linked to the extent of T cell infiltration in the BM of pediatric AML, in line with data from 237 (preclinical) studies in other cancers^{40, 42}.

238 **T cells cluster into aggregates in the bone marrow of pediatric AML**

239 Several studies in solid cancers have identified the presence of immune aggregates in the 240 tumor microenvironment, such as T- and B cell-rich structures resembling secondary 241 Iymphoid organs (TLSs) and T cell-rich structures lacking B cells^{23-25, 43, 44}. These aggregates 242 may represent sites of priming or re-activation of anti-tumor immune responses and have 243 been associated with better responses to immune checkpoint inhibitors in many cancers 244 types^{23-28, 45, 46}. As TLSs and other immune aggregates often develop at sites of chronic 245 inflammation²³⁻²⁵, we next asked whether similar structures were present in the BM of 246 immune-infiltrated pediatric AML cases. Accordingly, we first investigated the number of T 247 cell networks in pediatric immune-infiltrated (n=22), immune-depleted (n=50), and non-248 leukemic BM biopsies ($n=10$). In this analysis, T cell networks were defined as at least ten 249 directly interacting T cells (≤10 μm between adjacent nuclei), to avoid classifying randomly 250 dispersed T cells as networks (Fig. $3A$)⁴⁴. We found that T cell networks were present in 251 both AML groups and controls, although they were significantly more frequent in the BM of 252 immune-infiltrated compared to immune-depleted cases (*P*<0.001; **Fig. 3B** and **Table S1**; 253 representative image of a T cell network shown in **Fig. 3C**). Moreover, controls had 254 significantly more T cell networks in comparison to immune-depleted cases (*P*=0.027; **Fig.** 255 **3B;** representative images of immune-depleted biopsies shown in **Fig. S3A-B**).

256 In addition, we identified large T cell networks, defined as at least 100 directly 257 interacting T cells (**Fig. 3D**), to be more abundant in the BM of immune-infiltrated compared 258 to immune-depleted cases (*P*<0.001; **Fig. 3E;** representative image shown in **Fig. 3F**). 259 *KMT2A*-rearranged (9/17 cases; 53%) and complex karyotype AML (3/17 cases; 18%) were 260 the most common cytogenetic subgroups among cases with large T cell networks (n=17 in 261 total; **Table S1**). These large networks often colocalized with a dense network of B cells in 262 immune-infiltrated cases (termed 'lymphoid aggregates'; LA; **Fig. 3G;** 9/15 cases; 60%); 263 representative images shown in **Fig. 3H-I, Fig. S3C-D**; 0/2 immune-depleted cases). 264 However, the LAs identified in pediatric AML patients were not organized in a fashion seen 265 in mature TLSs with an inner zone of B cells surrounded by T cells²³⁻²⁵. Instead, T- and B 266 cells appeared to be mixed throughout the aggregate, as seen in immature TLSs and other 267 immune aggregates (representative images shown in Fig. 3H-I and Fig. S3C-D)^{25, 43}. In the 268 BM of non-leukemic control biopsies, we did not identify LAs or large T cell-dominant 269 networks with no or sparse B cells (representative image shown in **Fig. S3E**). Taken 270 together, these data show that large networks of T cells, both with and without colocalizing B 271 cells, are frequent in the BM of treatment-naïve immune-infiltrated pediatric AML cases.

272 Given that TLSs and other immune aggregates may function as sites of intratumoral 273 immune priming that can lead to successful anti-tumor immunity in solid cancers^{23-28, 45-48}. 274 they may also serve as markers of leukemia-specific immune responses in hematological 275 malignancies. Consequently, we performed pilot work to explore whether responses to 276 immune checkpoint inhibitors were associated with the presence of LAs and/or large T cell-277 dominant networks in the AML BM. As data from pediatric AML cases treated with such 278 therapies were not available, we applied multiplex immunofluorescence to pre- and post-279 treatment BM biopsies of transplant-naïve and post-transplant adult AML cases (three 280 responders and three non-responders) treated with both ipilimumab and decitabine in the 281 context of a clinical trial (NCT02890329^{13, 17}; Fig. S4A). Accordingly, BM biopsies collected 282 at baseline, time of best response, and end of treatment were stained with antibodies 283 against CD3, CD20, and CD34 (n=17 in total; representative images of LAs and large T cell-284 dominant networks are shown in **Fig. S4B-D**; patient characteristics are depicted in **Table** 285 **S3**). LAs were only observed in responders (response definitions in Supplementary 286 Methods), although their time of appearance differed (**Fig. S4E-J**). Large T cell-dominant 287 networks were present in two responders at baseline and at time of best response 288 (AML1002 + AML1006; **Fig. S4E**,**G**). Among non-responders, one patient had large T cell-289 dominant networks at baseline (AML1010; **Fig. S4I**). Like pediatric AML, T- and B cells in 290 lymphoid aggregates were not organized in distinct zones (**Fig. S4B-C**). Thus, in this 291 exploratory analysis, we found that large T cell-dominant networks were present both at

292 baseline and at time of best response in two out of three responders, whereas LAs were 293 present in all three responders but at different time points. Although the patient 294 heterogeneity and small cohort size preclude conclusions regarding the predictive utility of 295 lymphoid aggregates and T cell dominant networks, our preliminary findings encourage 296 future investigations into the association between immune aggregates and ICI response in 297 both adult and pediatric AML, as done in solid cancers $^{26-28,45}$.

298 **Spatial transcriptomics unravels the composition of lymphoid aggregates in the bone** 299 **marrow of pediatric AML**

300 The identification of LAs prompted us to explore whether the profiles of these aggregates 301 shared similarities with TLSs in solid cancers (i.e. several T cell subsets, germinal center B 302 cells, plasma cells, dendritic cells)²³⁻²⁵. To accurately identify TLSs, several transcriptomic 303 signatures have been proposed²⁵: a 12-gene chemokine signature⁴⁹ ('12chem'; reflective of 304 TLSs independent of their maturation stage), an 8-gene follicular helper T cell signature⁵⁰ 305 ('Tfh'; reflective of mature TLSs), and a 29-gene TLS imprint signature²⁷ (reflective of mature 306 TLSs). We aimed to examine the expression of these signatures in both LA and BM regions 307 without such aggregates. Towards this aim, we performed spatial transcriptomics using the 308 GeoMx spatial transcriptomics platform³⁰ on eight BM biopsies: four immune-infiltrated AML 309 biopsies with LAs, and four reference biopsies (two immune-infiltrated AML biopsies without 310 LAs and two non-leukemic control biopsies; patient characteristics are depicted in **Table S1**). 311 Regions of interest (ROIs) included areas with LAs, 'mixed' areas containing leukemic cells 312 and various other populations, and 'control' areas in the non-leukemic BM (region types are 313 illustrated in **Fig. 4A-C;** representative images of ROI selection are shown in **Fig. S5A**). In 314 total, we successfully sequenced 143 regions with an average of 335 cells per region (range: 315 126 to 826 cells): 35 LA regions, 92 mixed regions, and 16 control regions. Our analysis 316 revealed two main clusters of regions in the UMAP: cluster 1 contained both regions with 317 LAs and mixed regions from biopsies with LAs, while cluster 2 consisted of mixed regions 318 from biopsies without these aggregates, and control regions (**Fig. 4D**). Consequently, we 319 divided mixed regions in two distinct groups: areas from biopsies with LAs (MIXED1, N=48), 320 and those from biopsies without such aggregates (MIXED2, N=44). All three TLS-specific 321 gene signatures were significantly enriched in LA regions in comparison to both mixed- and 322 control regions (**Fig. 4E-F** and **S5B**). Thus, while the identified LAs lacked the typical 323 organization of mature TLS, we did identify enrichment of the Tfh- and TLS imprint 324 signatures representative of mature TLSs.

325 To gain insight into differences in immune and stromal cell types between LA and 326 other BM regions, we performed immune deconvolution by integrating spatial transcriptomic

327 data with single-cell (sc) and flow-sorted bulk RNA-sequencing data of microenvironmental 328 cell populations⁵¹. This analysis revealed that LA regions had an increased abundance of 329 CD4⁺ T cells, CD8⁺ T cells, non-plasma B cells, plasma cells, and macrophages (Fig. 4G-K). 330 In both LA and MIXED1-regions, the $CD4^{\text{+}}:\text{CD8}^+$ T cell ratio was lower compared to 331 MIXED2- and control regions (approximately 1:1 in both vs. 2:1 and 3:1, respectively; **Fig. S5C**), indicating a relatively higher abundance of CD8⁺ T cells in the former regions. When 333 considering macrophage polarization, we noted a significantly lower M2-predominance score 334 in LA regions compared to both mixed regions, consistent with the negative correlation 335 between M2-predominance and BM T cell infiltration observed above (**Fig. 4L**; **Fig. 2F**). 336 Moreover, endothelial cells and fibroblasts were enriched in LA regions compared to 337 MIXED1-regions (**Fig. S5D-E**). Additionally, NK- and dendritic cells were distributed evenly 338 across AML biopsies, while MIXED2 regions had a significantly higher abundance of 339 neutrophils compared to both LA and MIXED1-regions (**Fig. S5F-H**). To confirm our 340 deconvolution results, we performed differential gene expression analysis between LA, 341 mixed, and control regions. In LA regions compared to non-aggregate regions within the 342 same biopsies (MIXED1), we found upregulation of many T- and B cell genes (e.g., *CD3D,* 343 *CD8B, CD79A*), as well as genes associated with TLS formation in solid cancers (*LTB,* 344 *CCL19)* and B cell recruitment *(CXCL13*; **Fig. S6A**). Furthermore, immunoglobulin-related 345 genes (*IGHG1*, *IGHG3*, *IGHG4*, *IGKC*) were significantly enriched in LA compared to 346 MIXED1-regions, consistent with an increased abundance of plasma and/or memory B cells 347 (**Fig. S6A**). Similar results were observed when comparing LA regions with MIXED2- and 348 control regions (**Table S4**).

349 Given the combination of a lack of distinct T- and B cell zones and an increased 350 estimated abundance of plasma cells in these LAs, we next sought to perform a more in-351 depth characterization of the B cells in these regions. To do so, we again applied immune 352 deconvolution by integrating our spatial transcriptomic data with another scRNA-sequencing 353 reference dataset (**Fig. 5A**). In this case, we used a comprehensive scRNA-sequencing 354 dataset of pediatric tonsillar B cells⁵², which included naïve B cells, germinal center B cells, 355 plasmablasts, and memory B cells, as a reference. In line with the lack of a follicle-like 356 morphology of LAs, we did not identify germinal center B cells in these regions (**Fig. 5B**). 357 Similarly, naïve B cells were absent. The most abundant B cells were memory B cells, while 358 a smaller fraction consisted of plasmablasts, together indicating the presence of 359 differentiated B cell subsets in these aggregates (**Fig. 5B**). Since LA regions showed 360 increased expression of the cytotoxicity-related genes *GZMA* and *GZMK* compared to neighboring regions (**Fig. S6A**), we also aimed to investigate the cytotoxic capacity of CD8+ 361 362 T cells in these regions. Accordingly, we performed immune deconvolution of our spatial

363 transcriptomic dataset using a scRNA-sequencing dataset of BM CDB^+ T cells from adult 364 AML patients¹⁶. This reference dataset included naïve-, memory-, cytotoxic- (CTL), mucosal-365 associated invariant T- (MAIT), and 'dysfunctional' CD8⁺ T cells. The CD8⁺ T cells classified 366 as dysfunctional were characterized by increased expression of multiple immune checkpoint 367 receptor (IR) genes, such as *PDCD1*, *LAG3*, and *HAVCR2*, and reduced expression of 368 cytotoxicity-related genes such as *GZMB*, *GNLY*, and *PRF1*. Notably, deconvolution 369 revealed that these potentially dysfunctional CD8⁺ T cells were enriched in LA regions 370 compared to mixed- and control regions, at the expense of both naïve- and cytotoxic CDB^+ T 371 cells (**Fig. 5C-D**). Moreover, memory CD8⁺ T cells were not identified in any of the biopsies. 372 The increased proportion of potentially dysfunctional CD8⁺ T cells in LA regions prompted us 373 to investigate whether these T cells were truly dysfunctional (i.e. no cytotoxic potential). 374 Accordingly, we examined the expression of the cytotoxicity marker granzyme B (GZMB) in 375 CD8⁺ T cells that expressed at least two immune checkpoint receptor markers (IR⁺⁺/⁺⁺⁺; PD-376 1, LAG3, and/or TIM-3) in a subset of the LA-rich biopsies that had been characterized using 377 spatial transcriptomics (n=2 biopsies with six LAs in total). Using multiplex 378 immunofluorescence with antibodies against CD3, CD8, PD-1, LAG3, TIM-3, and GZMB, in 379 combination with standard IHC for CD20, we identified that 58% (range: 30 to 100%) of 380 CD3⁺CD8⁺IR^{++/+++} T cells in LAs expressed GZMB (representative images shown in Fig. 5E; **Fig. 5F**), suggesting that more than half of the potentially dysfunctional CD8⁺ T cells still had 382 cytotoxic capacity. In addition, since TLS-associated regulatory T cells (Tregs) have been 383 found to attenuate the positive prognostic effect of TLS-associated $CDS⁺$ T cells in human 384 non-small cell lung cancer, colorectal cancer, and soft tissue sarcoma^{45, 53, 54}, we assessed 385 the presence of putative Tregs (CD3⁺FOXP3⁺) in LAs in the same subset of biopsies (n=2). 386 In the six examined LAs, we observed very few Tregs (<1%), suggesting that Tregs are 387 hardly present in LAs in pediatric AML (representative image shown in **Fig. S6B; Fig. S6C**). 388 Taken together, our integrative spatial analyses demonstrate that LAs in the BM of pediatric 389 AML are specifically enriched for CD8⁺ T cells, memory B cells, plasma cells and/or 390 plasmablasts, and M1-like macrophages. Despite the lack of germinal center B cells and 391 separate T- and B cell zones, the presence of memory B cells, plasma cells and/or 392 plasmablasts, and immunoglobulin gene expression suggests that LAs in pediatric AML are 393 sites of B cell differentiation. Furthermore, the presence of CD8⁺ T cells expressing multiple 394 immune checkpoint markers, yet not fully exhausted, within LAs, encourages future 395 investigations into the potential of leveraging these LA-associated T cells for 396 immunotherapeutic efficacy.

397 **Discussion**

398 In this study, we performed a multidimensional assessment of the tumor immune 399 microenvironment in pediatric AML. We demonstrated that nearly one-third of pediatric AML 400 cases has an immune-infiltrated BM, which is characterized by a decreased M2-:M1-like 401 macrophage ratio. Furthermore, we detected the presence of large T cell networks, both with 402 and without colocalizing B cells, in the BM and dissected the cellular composition of T- and B 403 cell-rich aggregates using spatial transcriptomics. These analyses revealed that these LAs 404 are hotspots of CD8⁺ T cells, memory B cells, plasma cells and/or plasmablasts, and M1-like 405 macrophages. Collectively, our study provides a multidimensional characterization of the BM 406 immune microenvironment in pediatric AML and indicates starting points for further 407 investigations into immunomodulatory mechanisms in this devastating disease.

408 Understanding the prevalence of distinct immune phenotypes and associated 409 targetable immune-evasion mechanisms in the BM of pediatric AML is key for better 410 prospective selection of patients in future immunotherapy trials^{33, 45}. Although we identified a 411 subset with high abundance of T cells, many pediatric AML cases had an immune-depleted 412 BM microenvironment. We observed that *FLT3*-ITD and/or *NPM1* mutations were associated 413 with low T cell infiltration in the BM of pediatric AML, consistent with data in adult AML^{33} . 414 Although we did not investigate the direct consequences of these molecular alterations, such 415 as alterations in the expression of immunomodulatory surface molecules^{38, 39}, we identified 416 M2-like macrophage predominance in immune-depleted cases. The observed negative 417 correlation between the M2-:M1-like macrophage ratio and the extent of T cell infiltration is 418 consistent with data from (preclinical) studies in other cancers, suggesting a role for M2-like 419 macrophages (or a lack of M1-like macrophages) in limiting T cell infiltration to the leukemic 420 BM^{40, 41}. Consequently, targeting M2-like macrophages (e.g., using checkpoint blockade) to 421 overcome their immunosuppressive functions could be an attractive therapeutic strategy for 422 immune-depleted $AML^{55, 56}$.

423 In addition, our integrative spatial analyses showed that T cells in the BM can be 424 organized into multicellular aggregates. Although T- and B cell-rich LAs did not contain 425 distinct T- and B cell zones and germinal center B cells typically seen in mature TLSs in solid 426 cancers, the localized enrichment of memory B cells, plasma cells and/or plasmablasts, and 427 immunoglobulin gene expression suggests that these aggregates are sites of B cell 428 maturation. Moreover, the 1:1 ratio of $CD4^+$ and $CD8^+$ T cells observed in LAs has also been 429 associated with mature $T\text{LSS}^{57}$. Notably, CD8⁺ T cells in LAs were found to be in different 430 cell states, including a subset that expressed multiple immune checkpoint markers. GZMB-431 expression was identified in more than half of these cells, suggesting that these CD8⁺ T cells 432 are not fully exhausted and may be susceptible to ICI therapy⁵⁸. In addition to T- and B cell-433 rich immune aggregates, we detected large T cell networks with sparse B cells. Since these

434 networks have also been associated with ICI response in solid cancers, further 435 investigations into the different types of immune aggregates in AML and their relevance for 436 immunotherapy response are needed^{43, 46, 59, 60}. For instance, do large T cell-dominant 437 networks relate to LAs, and do they (differentially) associate with ICI efficacy in AML? Since 438 TLS are considered to be sites where tumor-specific T- and B cell immune responses may 439 be generated²³⁻²⁵, future research also needs to investigate whether immune aggregates in 440 AML are tumor-directed.

441 Altogether, our analyses deepen the understanding of the BM immune 442 microenvironment in AML and provides an impetus to explore how intratumoral immune 443 aggregates could be exploited for improving immunotherapy outcomes. Further, our work 444 provides a framework for leveraging spatial transcriptomics to interrogate the spatial 445 organization of the leukemic BM. Advances in spatial transcriptomic techniques now allow 446 for investigating the spatial dimension of hematological malignancies at subcellular 447 resolution, opening an exciting path towards new discoveries in the field of $AML^{61, 62}$.

- 448
- 449
- 450
- 451

452

453

454

455

456

457

- 458
- 459 460
- 461

- 463
-
- 464

- 465
- 466
- 467
- 468
- 469

470 **Acknowledgements**

471 We would like to thank all patients and/or their families for their generous consent for the 472 research use of these samples; the staff of the University Medical Center Utrecht Tissue 473 Facility for their excellent immunohistochemistry service (Domenico Castigliego, Petra van 474 der Weide, Petra van der Kraak, Erica Siera, Karina Timmer, Sven van Kempen), and the 475 team at Utrecht Sequencing Facility for performing the NanoString experiments (nCounter 476 and GeoMx) and for providing assistance with data-analysis (dr. Ies Nijman, Robin Geene, 477 Pim Kloosterman); dr. Thierry van den Bosch, dr. Ravian van Ineveld, Ella de Boed, Nienke 478 van Herk, Thijs van den Broek, Maurice de Haan, and Susanne Gamas Vis provided help 479 with imaging experiments and/or analysis; Dr. Matthew S. Davids for clinical data of patients 480 treated on ETCTN/CTEP 9204; Dr. Ivette Deckers and dr. Annette Gijsbers (PALGA) 481 performed essential work for the acquisition of bone biopsies from other hospitals; prof. dr. 482 Gertjan Kaspers and dr. Bianca Goemans aided with identifying potential patients, the 483 biobank staff (Jantien Woudstra, Marion Koopmans, dr. Edwin Sonneveld) helped to identify 484 patient material, and Arie Maat aided with the sectioning of bone biopsy sections; dr. 485 Caroline Lindemans, members from the Heidenreich group (dr. Katarzyna Szoltysek, dr. 486 Farnaz Barneh, dr. Mauricio Ferrao-Blanco, Elizabeth Schweighart, Nina van der Wilt), the 487 Van Heesch group (dr. Ana Pinheiro-Lopes), and the single-cell sequencing facility (dr. Lindy 488 Visser) at the Princess Máxima Center for Pediatric Oncology for carefully reading the 489 manuscript and/or fruitful discussions. Figures have been created using BioRender.com.

490 **Author contributions**

491 Conceptualization: J.B.K, I.W., M.A.V., S.N., M.B., C.M.Z., O.H. Methodology: J.B.K, I.W.,

- 492 M.A.V., M.F., S.N., M.B., C.M.Z., O.H. Data acquisition: J.B.K., M.A.V., F.B., J.I.M.-E. H.G.-
- 493 K., R.M, K.B.C., B.P., K.P., H.H. Data analysis and interpretation: J.B.K., I.W., L.P., F.B.,
- 494 A.P., J.I.M.-E., J.S.G., S.J.R., C.J.W., H.H. Writing Original Draft: J.B.K.; Writing –
- 495 Reviewing & Editing: all authors; Supervision: S.N., M.B., C.M.Z., O.H.

496 **Competing interests:**

- 497 J.S.G. reports serving on steering committee and receiving personal fees from AbbVie,
- 498 Genentech, and Servier and institutional research funds from AbbVie, Genentech, Pfizer,
- 499 and AstraZeneca.
- 500 S.R. receives research support from Bristol-Myers-Squibb and KITE/Gilead, and is a
- 501 member of the SAB of Immunitas Therapeutics.
- 502 C.J.W. holds equity in BioNTech, Inc and receives research support from Pharmacyclics.
- 503 C.M.Z. receives institutional research support from Pfizer, Abbvie, Takeda, Jazz, Kura,
- 504 Gilead, and Daiichi Sankyo, provides consultancy services for Kura, Bristol-Myers-Squibb,
- 505 Novartis, Gilead, Incyte, and Syndax, and serves on advisory committees for Novartis,
- 506 Sanofi, and Incyte.
- 507 O.H. receives institutional research support from Syndax and Roche.
- 508 The remaining authors declare no competing financial interests.

509 **Data availability**

- 510 Sequencing data can be accessed from the Gene Expression Omnibus (nCounter data:
- 511 GSEXXX; GeoMx data: GSEXXX; both normalized counts [GSE IDs will be available upon
- 512 approval]) and from the European Genome-phenome Archive (EGA) database (https://ega-
- 513 archive.org/studies/EGAXXX; raw nCounter and GeoMx data [idem]).

514 **Funding**

515 This work has been funded in part by a KIKA (329) program grant to O.H. L.P. is a Scholar 516 of the American Society of Hematology, participant in the BIH Charité Digital Clinician 517 Scientist Program funded by the DFG, the Charité – Universitätsmedizin Berlin, and the 518 Berlin Institute of Health at Charité (BIH) and is supported by the Max-Eder program of the 519 German Cancer Aid. J.S.G. is supported by the Conquer Cancer Foundation Career 520 Development Award, Leukemia and Lymphoma Society Translational Research Program 521 Award, and NIH K08CA245209. NCI CTEP provided study drug (Ipilimumab) support.

522 This work was supported by National Institutes of Health, National Cancer Institute grant 523 P01CA229092 (C.J.W.), UM1CA186709 (Principal Investigator: Geoffrey Shapiro), National 524 Cancer Institute Cancer Therapy Evaluation Program, Bristol-Myers Squibb, and LLS 525 Therapy Accelerator Program. This work was further supported by the CIMAC-CIDC 526 Network. Scientific and financial support for the CIMAC-CIDC Network is provided through 527 National Institutes of Health, National Cancer Institute Cooperative Agreements 528 U24CA224319 (to the Icahn School of Medicine at Mount Sinai CIMAC), U24CA224331 (to 529 the Dana-Farber Cancer Institute CIMAC), U24CA224285 (to the MD Anderson Cancer

- 530 Center CIMAC), U24CA224309 (to the Stanford University CIMAC), and U24CA224316 (to
- 531 the CIDC at Dana-Farber Cancer Institute). The CIMAC-CIDC website is found at
- 532 https://cimac-network.org/.

534 **References**

- 535 1. Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in cancer 536 prognosis and therapeutic efficacy. Nat Rev Cancer 2020;20:662-680.
- 537 2. Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint 538 inhibitor immunotherapy. Nat Rev Cancer 2019;19:133-150.
- 539 3. Belmontes B, Sawant DV, Zhong W, et al. Immunotherapy combinations overcome 540 resistance to bispecific T cell engager treatment in T cell-cold solid tumors. Sci Transl
541 Med 2021;13. Med 2021;13.
- 542 4. Vadakekolathu J, Rutella S. Escape from T-cell-targeting immunotherapies in acute 543 myeloid leukemia. Blood 2024;143:2689-2700.
- 544 5. Gröbner SN, Worst BC, Weischenfeldt J, et al. The landscape of genomic alterations 545 across childhood cancers. Nature 2018;555:321-327.
- 546 6. Majzner RG, Heitzeneder S, Mackall CL. Harnessing the Immunotherapy Revolution
547 for the Treatment of Childhood Cancers. Cancer Cell 2017;31:476-485. for the Treatment of Childhood Cancers. Cancer Cell 2017;31:476-485.
- 548 7. Pfister SM, Reyes-Múgica M, Chan JKC, et al. A Summary of the Inaugural WHO 549 Classification of Pediatric Tumors: Transitioning from the Optical into the Molecular 550 Era. Cancer Discov 2022;12:331-355.
- 551 8. Koedijk JB, van der Werf I, Calkoen FG, et al. Paving the Way for Immunotherapy in
552 Pediatric Acute Myeloid Leukemia: Current Knowledge and the Way Forward. 552 Pediatric Acute Myeloid Leukemia: Current Knowledge and the Way Forward.
553 Cancers (Basel) 2021;13. 553 Cancers (Basel) 2021;13.
- 554 9. Daver N, Garcia-Manero G, Basu S, et al. Efficacy, Safety, and Biomarkers of 555 Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid 556 Leukemia: A Nonrandomized, Open-Label, Phase II Study. Cancer Discov 557 2019;9:370-383.
- 558 10. Uy GL, Aldoss I, Foster MC, et al. Flotetuzumab as salvage immunotherapy for 559 refractory acute myeloid leukemia. Blood 2021;137:751-762. 559 refractory acute myeloid leukemia. Blood 2021;137:751-762.
- 560 11. Vadakekolathu J, Minden MD, Hood T, et al. Immune landscapes predict 561 chemotherapy resistance and immunotherapy response in acute myeloid leukemia. 562 Sci Transl Med 2020;12.
- 563 12. Davids MS, Kim HT, Bachireddy P, et al. Ipilimumab for Patients with Relapse after 564 Allogeneic Transplantation. N Engl J Med 2016;375:143-53.
- 565 13. Garcia JS, Flamand Y, Penter L, et al. Ipilimumab plus decitabine for patients with 566 [566] 566 566 MDS or AML in posttransplant or transplant-naïve settings. Blood 2023;141:1884- 567 1888.
- 568 14. Ravandi F, Subklewe M, Walter RB, et al. Safety and tolerability of AMG 330 in 569 adults with relapsed/refractory AML: a phase 1a dose-escalation study. Leuk 570 Lymphoma 2024:1-11.
- 571 15. Zeidner JF, Vincent BG, Ivanova A, et al. Phase II Trial of Pembrolizumab after High-572 Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Blood Cancer 573 Discov 2021;2:616-629.
- 574 16. Desai PN, Wang B, Fonseca A, et al. Single-Cell Profiling of CD8+ T Cells in Acute 575 Myeloid Leukemia Reveals a Continuous Spectrum of Differentiation and Clonal 576 Hyperexpansion. Cancer Immunol Res 2023:Of1-of18.
- 577 17. Penter L, Liu Y, Wolff JO, et al. Mechanisms of response and resistance to combined 578 decitabine and ipilimumab for advanced myeloid disease. Blood 2023;141:1817- 579 1830.
- 580 18. Bailur JK, McCachren SS, Pendleton K, et al. Risk-associated alterations in marrow 581 T cells in pediatric leukemia. JCI Insight 2020;5.
- 582 19. Rutella S, Vadakekolathu J, Mazziotta F, et al. Immune dysfunction signatures 583 predict outcomes and define checkpoint blockade-unresponsive microenvironments 584 in acute myeloid leukemia. J Clin Invest 2022;132.
- 585 20. Lasry A, Nadorp B, Fornerod M, et al. An inflammatory state remodels the immune 586 microenvironment and improves risk stratification in acute myeloid leukemia. Nat 587 Cancer 2023;4:27-42.

- 588 21. Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with 589 combination immunotherapies. Nat Rev Drug Discov 2019;18:197-218.
- 590 22. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by
591 inhibiting adaptive immune resistance. Nature 2014;515:568-71. inhibiting adaptive immune resistance. Nature 2014;515:568-71.
- 592 23. Schumacher TN, Thommen DS. Tertiary lymphoid structures in cancer. Science 593 2022;375:eabf9419.
- 594 24. Fridman WH, Meylan M, Petitprez F, et al. B cells and tertiary lymphoid structures as 595 determinants of tumour immune contexture and clinical outcome. Nat Rev Clin Oncol
- 596 2022;19:441-457.
597 25. Fridman WH, Mey 25. Fridman WH, Meylan M, Pupier G, et al. Tertiary lymphoid structures and B cells: An 598 intratumoral immunity cycle. Immunity 2023;56:2254-2269.
- 599 26. Helmink BA, Reddy SM, Gao J, et al. B cells and tertiary lymphoid structures 600 promote immunotherapy response. Nature 2020;577:549-555.
- 601 27. Meylan M, Petitprez F, Becht E, et al. Tertiary lymphoid structures generate and 602 propagate anti-tumor antibody-producing plasma cells in renal cell cancer. Immunity 603 2022;55:527-541.e5.
- 604 28. Vanhersecke L, Brunet M, Guégan JP, et al. Mature tertiary lymphoid structures
605 predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 605 predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 606 expression. Nat Cancer 2021;2:794-802.
- 607 29. Casparie M, Tiebosch AT, Burger G, et al. Pathology databanking and biobanking in 608 The Netherlands, a central role for PALGA, the nationwide histopathology and 609 cytopathology data network and archive. Cell Oncol 2007;29:19-24.
- 610 30. Merritt CR, Ong GT, Church SE, et al. Multiplex digital spatial profiling of proteins and 611 RNA in fixed tissue. Nat Biotechnol 2020;38:586-599.
- 612 31. van Galen P, Hovestadt V, Wadsworth Ii MH, et al. Single-Cell RNA-Seq Reveals 613 AML Hierarchies Relevant to Disease Progression and Immunity. Cell 614 2019;176:1265-1281.e24.
- 615 32. Brück O, Dufva O, Hohtari H, et al. Immune profiles in acute myeloid leukemia bone 616 marrow associate with patient age, T-cell receptor clonality, and survival. Blood Adv 617 2020;4:274-286.
- 618 33. Dufva O, Pölönen P, Brück O, et al. Immunogenomic Landscape of Hematological 619 Malignancies. Cancer Cell 2020;38:380-399.e13.
- 620 34. Bolouri H, Farrar JE, Triche T, Jr., et al. The molecular landscape of pediatric acute 621 myeloid leukemia reveals recurrent structural alterations and age-specific mutational 622 interactions. Nat Med 2018;24:103-112.
- 623 35. Newman AM, Steen CB, Liu CL, et al. Determining cell type abundance and 624 expression from bulk tissues with digital cytometry. Nat Biotechnol 2019;37:773-782.
- 625 36. Wang Y, Cai YY, Herold T, et al. An Immune Risk Score Predicts Survival of Patients 626 with Acute Myeloid Leukemia Receiving Chemotherapy. Clin Cancer Res 627 2021;27:255-266.
- 628 37. Koedijk JB, van Beek TB, Vermeulen MA, et al. Case Report: Immune dysregulation 629 associated with long-lasting regression of a (pre)leukemic clone. Front Immunol 630 2023;14:1280885.
- 631 38. Austin RJ, Straube J, Halder R, et al. Oncogenic drivers dictate immune control of 632 acute myeloid leukemia. Nat Commun 2023;14:2155.
- 633 39. Straube J, Janardhanan Y, Haldar R, et al. Immune control in acute myeloid 634 leukemia. Exp Hematol 2024:104256.
635 40. House IG, Savas P, Lai J, et al. M
- 635 40. House IG, Savas P, Lai J, et al. Macrophage-Derived CXCL9 and CXCL10 Are 636 Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. 637 Clin Cancer Res 2020;26:487-504.
- 638 41. Italiani P, Boraschi D. From Monocytes to M1/M2 Macrophages: Phenotypical vs.
- 639 Functional Differentiation. Front Immunol 2014;5:514.
640 42. Jiang P, Gu S, Pan D, et al. Signatures of T cell dy 640 42. Jiang P, Gu S, Pan D, et al. Signatures of T cell dysfunction and exclusion predict 641 cancer immunotherapy response. Nat Med 2018;24:1550-1558.

- 642 43. Laumont CM, Nelson BH. B cells in the tumor microenvironment: Multi-faceted 643 organizers, regulators, and effectors of anti-tumor immunity. Cancer Cell 644 2023;41:466-489.
- Gaglia G, Burger ML, Ritch CC, et al. Lymphocyte networks are dynamic cellular 646 communities in the immunoregulatory landscape of lung adenocarcinoma. Cancer 647 Cell 2023;41:871-886.e10.
- 648 45. Italiano A, Bessede A, Pulido M, et al. Pembrolizumab in soft-tissue sarcomas with 649 tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort. Nat Med
- 650 2022;28:1199-1206. 651 46. Siddiqui I, Schaeuble K, Chennupati V, et al. Intratumoral Tcf1(+)PD-1(+)CD8(+) T 652 Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination
653 and Checkpoint Blockade Immunotherapy. Immunity 2019;50:195-211.e10. 653 and Checkpoint Blockade Immunotherapy. Immunity 2019;50:195-211.e10.
- 654 47. Cottrell TR, Thompson ED, Forde PM, et al. Pathologic features of response to 655 neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for 656 quantitative immune-related pathologic response criteria (irPRC). Ann Oncol 657 2018;29:1853-1860.
- 658 48. van Dijk N, Gil-Jimenez A, Silina K, et al. Preoperative ipilimumab plus nivolumab in 659 locoregionally advanced urothelial cancer: the NABUCCO trial. Nat Med 660 2020;26:1839-1844.
- 661 49. Coppola D, Nebozhyn M, Khalil F, et al. Unique ectopic lymph node-like structures 662 present in human primary colorectal carcinoma are identified by immune gene array 663 profiling. Am J Pathol 2011;179:37-45.
- 664 50. Gu-Trantien C, Loi S, Garaud S, et al. CD4⁺ follicular helper T cell infiltration predicts 664 50. Gu-Trantien C, Loi S, Garaud S, et al. CD4* follicular helper T cell infiltration predicts
665 breast cancer survival. J Clin Invest 2013;123:2873-92.
666 51. Danaher P, Kim Y, Nelson B, et al. Advance 665 breast cancer survival. J Clin Invest 2013;123:2873-92.
- 667 quantification of cell types in spatial transcriptomic data. Nat Commun 2022;13:385.
- 668 52. King HW, Orban N, Riches JC, et al. Single-cell analysis of human B cell maturation 669 predicts how antibody class switching shapes selection dynamics. Sci Immunol 670 2021;6.
- 671 53. Devi-Marulkar P, Fastenackels S, Karapentiantz P, et al. Regulatory T cells infiltrate 672 the tumor-induced tertiary lymphoïd structures and are associated with poor clinical 673 outcome in NSCLC. Commun Biol 2022;5:1416.
- 674 54. Schweiger T, Berghoff AS, Glogner C, et al. Tumor-infiltrating lymphocyte subsets 675 and tertiary lymphoid structures in pulmonary metastases from colorectal cancer. Clin 676 Exp Metastasis 2016;33:727-39.
- 55. Brauneck F, Fischer B, Witt M, et al. TIGIT blockade repolarizes AML-associated 678 TIGIT(+) M2 macrophages to an M1 phenotype and increases CD47-mediated 679 phagocytosis. J Immunother Cancer 2022;10.
- 680 56. Perzolli A, Koedijk JB, Zwaan CM, et al. Targeting the innate immune system in 681 pediatric and adult AML. Leukemia 2024;38:1191-1201.
- 682 57. Vaccaro A, Yang F, van de Walle T, et al. Cellular and molecular events organizing
683 the assembly of tertiary lymphoid structures in glioblastoma. bioRxiv 683 the assembly of tertiary lymphoid structures in glioblastoma. bioRxiv 684 2024:2024.07.04.601824.
- 685 58. Philip M, Schietinger A. CD8(+) T cell differentiation and dysfunction in cancer. Nat 686 Rev Immunol 2022;22:209-223.
- 687 59. Chen JH, Nieman LT, Spurrell M, et al. Spatial analysis of human lung cancer
688 secognalized immune hubs enriched for stem-like CD8 T cells and associated reveals organized immune hubs enriched for stem-like CD8 T cells and associated 689 with immunotherapy response. bioRxiv 2023.
- 690 60. Jansen CS, Prokhnevska N, Master VA, et al. An intra-tumoral niche maintains and 691 differentiates stem-like CD8 T cells. Nature 2019;576:465-470.
- 692 61. He S, Bhatt R, Brown C, et al. High-plex imaging of RNA and proteins at subcellular 693 resolution in fixed tissue by spatial molecular imaging. Nat Biotechnol 2022;40:1794- 694 1806.

- 695 62. Janesick A, Shelansky R, Gottscho AD, et al. High resolution mapping of the tumor 696 microenvironment using integrated single-cell, spatial and in situ analysis. Nat 697 Commun 2023;14:8353.
-
- **Table Legends (tables are provided in a separate excel file)**
- **Supplementary Table 1. Clinical characteristics of the primary study cohort, supplemented with information on immune-infiltration, performed assays, and T cell networks.**
- **Supplementary Table 2. List of significantly up- or downregulated pathways comparing immune-infiltrated versus immune-depleted cases using ssGSEA.**
- **Supplementary Table 3. Clinical characteristics of the adult AML cohort treated with ipilimumab-based therapy.**
- **Supplementary Table 4. Differentially expressed genes (DEGs) between regions in the spatial transcriptomics (tx) dataset identified by linear mixed-effect modelling (LMM).**
- **Supplementary Table 5. Target antigens, antibody clones and suppliers of antibodies used for pediatric AML bone marrow IHC/multiplex immunofluorescence.**
- **Supplementary Table 6. Target antigens, antibody clones, suppliers, dilution of markers, diluents, and antigen retrieval conditions used for adult AML bone marrow multiplex immunofluorescence.**
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

729 **Figure Legends**

730 **Figure 1. Characterizing T cell infiltration in pediatric AML cases and non-leukemic** 731 **controls.** (A) Schematic overview of the study population, used techniques, and the digital 732 image analysis pipeline. AML cases are categorized in immune-infiltrated (red) and immune-733 depleted (blue) groups according to their T cell infiltration levels (above or below median of 734 non-leukemic controls). (B-C) Representative bone marrow biopsy images from a treatment-735 naïve pediatric AML case (B) and a non-leukemic control (C) showing H&E staining, $CD3^+$ T 736 cells, and $CDB⁺$ T cells. White lobules indicate adipocytes. (D-E) Comparison of the 737 normalized abundance of $CD3^+$ T cells (D) and $CD8^+$ T cells (E) in the bone marrow between 738 pediatric AML cases and non-leukemic controls using the Mann-Whitney test. The dashed 739 lines indicate the median $CD3⁺$ (D) and $CD8⁺$ (E) T cell abundance in non-leukemic controls, 740 respectively. (F-G) Normalized abundance of $CD3^+$ (F) and $CD8^+$ T cells (G) per cytogenetic 741 subgroup. 'Normal' indicates normal karyotype, while 'Others' is a merge of cytogenetic 742 abnormalities different from the five defined cytogenetic subgroups. See Table S1. 'Complex' 743 indicates cases with complex karyotype AML (≥3 chromosomal abnormalities). The dashed 744 lines shown in Figure 1D-E are also shown in Figure 1F-G. (H) Schematic overview of the 745 TARGET-AML cohort, the additional non-leukemic control group, the performed analysis 746 (CIBERSORTx), and the subsequent categorization of patients into the immune-infiltrated or 747 immune-depleted groups (based on median T- and $CDB⁺ T$ cell abundance in non-leukemic 748 controls). (I-J) Estimated absolute (ABS) abundance of $T-$ (I) and CD8⁺ T (J) cells in the 749 bone marrow of treatment-naïve pediatric AML cases in the TARGET-AML cohort. The 750 dashed lines shown in Figure 1I-J indicate the estimated median bone marrow T- and CDB^+ 751 T cell abundance in four non-leukemic controls.

752 **Figure 2. Transcriptional differences between immune-infiltrated and immune-**753 **depleted pediatric AML.** (A) Schematic overview of the study population, used techniques, 754 and analyses performed in Figure 2B-D. (B) Comparison of the normalized abundance of 755 CD20⁺ B cells in the bone marrow of pediatric AML (CD20 stains available for 69 cases) with 756 CD3⁺ T cell levels above or below the median of non-leukemic controls (later referred to as 757 immune-infiltrated and immune-depleted, respectively; Mann-Whitney test). (C) Volcano plot 758 of differentially expressed genes between immune-infiltrated (n=6) and immune-depleted 759 (n=17) pediatric AML bone marrow biopsies, identified using *DEseq2* with an FDR cut-off of 760 0.05 and minimum fold change (FC) of 2. (D) Single-sample gene set enrichment analysis of 761 differentially expressed genes between immune-infiltrated and immune-depleted cases using 762 the GO Biological Processes gene set with an FDR cut-off of 0.05. WikiPathways-related 763 results are shown in Table S2. (E) Schematic overview of the study populations for which 764 gene-expression data was available (primary study cohort and TARGET-AML cohort), and

765 the associated analysis. (F) Correlation plot of the negative correlation between the M2- 766 predominance score and the normalized number of CD3⁺ T cells, calculated using Spearman 767 correlation. (G) Comparison of the M2-predominance score between immune-infiltrated 768 (n=6) and immune-depleted (n=17) cases using the Mann-Whitney test. (H) Correlation plot 769 of the negative correlation between the M2-predominance score and the estimated 770 abundance of T cells in the bone marrow of TARGET-AML cases, calculated using 771 Spearman correlation. (I) Comparison of the M2-predominance score between immune-772 infiltrated (n=80) and immune-depleted (n=79) cases using the Mann-Whitney test.

773 **Figure 3. T cell networks in the bone marrow of pediatric AML.** (A) Illustration of the 774 identification of directly interacting T cells (above) and T cell networks (below) using 775 Delaunay Triangulation. (B) Comparison of the normalized abundance of T cell networks 776 between immune-infiltrated (n=22), immune-depleted (n=50), and non-leukemic control 777 biopsies (n=10; Kruskal-Wallis followed by Dunn's multiple comparisons test). (C) 778 Representative image of a T cell network in a treatment-naïve pediatric AML patient. (D) 779 Schematic of the definition of a large T cell network. (E) Comparison of the number of T cell 780 networks with at least 100 T cells/network between immune-infiltrated (n=22), immune-781 depleted (n=50), and non-leukemic control biopsies (n=10; Kruskal-Wallis followed by 782 Dunn's multiple comparisons test). (G) Schematic of the definition of a lymphoid aggregate. 783 (H-I) Representative images of lymphoid aggregates.

784 **Figure 4. Composition of lymphoid aggregates in immune-infiltrated pediatric AML.** 785 (A-C) Overview of the different types of regions profiled using spatial transcriptomics in 786 immune-infiltrated biopsies with lymphoid aggregates (A), immune-infiltrated biopsies without 787 lymphoid aggregates (B), and non-leukemic biopsies (C). Green cells indicate T cells, blue 788 cells indicate B cells, and pink/purple cells indicate AML blasts or normal myeloid cells. 789 These examples do not necessarily reflect the actual abundance of these subsets. LA: 790 lymphoid aggregate. (D) UMAP of transcriptomic profiles of various region types, organized 791 into two separate clusters. (E-F) Comparison of the expression of the 'Tfh' (E), and 'TLS 792 imprint' (F) signatures across different region types (Kruskal-Wallis followed by Dunn's 793 multiple comparisons test). (H-L) Deconvoluted abundance of various cell subsets and the 794 M2-predominance score compared across different region types (Kruskal-Wallis followed by 795 Dunn's multiple comparisons test). In case of multiple p-values, the upper one is associated 796 with the Kruskal-Wallis test, while the lower one(s) reflects the result of Dunn's multiple 797 comparison test.

798

800

801 **Figure 5**. **In-depth characterization of T- and B cells in lymphoid aggregates.** (A) 802 Schematic overview of the analysis approach applied to the spatial transcriptomics dataset 803 and the subsequent multiplex immunofluorescence (IF). scRNA-seq: single-cell RNA-804 sequencing. (B) Proportions of memory B cells, plasmablasts, and unassigned B cells in 805 lymphoid aggregates (LA). (C) Proportions of naïve-, cytotoxic (CTL), mucosal-associated 806 invariant T (MAIT)-, and potentially dysfunctional CD8⁺ T cells in lymphoid aggregate, mixed, 807 and control regions. (D) Comparison of the deconvoluted proportions of potentially 808 dysfunctional CD8⁺ T cells in lymphoid aggregate, mixed, and control regions (Kruskal-Wallis 809 followed by Dunn's multiple comparisons test). In case of multiple p-values, the upper one is 810 associated with the Kruskal-Wallis test, while the lower ones reflects the result of Dunn's 811 multiple comparison test. (E) Representative image of the multiplex immunofluorescence 812 analysis of a lymphoid aggregate. The names below each image indicate which antibodies 813 are shown. The green boxes on the lower row are zoomed in on the part of the biopsy in the 814 green box in the upper left image. (F) The proportion of CD3⁺CD8⁺ T cells that expressed 815 two or three inhibitor receptors $(\text{IR}^{++/++})$ positive (or not) for granzyme B (GZMB).

816 **Supplemental information titles and legends**

817 **Supplementary Figure 1. AML blasts and differentiation stage in relation to T- and** 818 **CD8⁺ T cell infiltration in the bone marrow.** (A) Comparison of the percentage of CD3⁺ T 819 cells out of all bone marrow (BM) cells between diagnostic pediatric AML cases with normal 820 karyotype and no identified molecular aberrations (wildtype) and those with a *FTL3*-ITD 821 and/or *NPM1* mutation (*NPM1*mut; Mann-Whitney test). The T cell proportions were 822 retrieved from diagnostic flow cytometry reports. These patients are part of an independent 823 cohort, not the primary study cohort. (B-C) Comparison of the CIBERSORTx-based 824 estimated absolute (ABS) abundance of T- (B) and CD8⁺ T cells (C) between pediatric AML 825 patients (TARGET-AML cohort) with different *KMT2A*-rearrangements. The names on the x-826 axis indicate the *KMT2A*-fusion partners. The dashed lines indicate the median estimated 827 abundance of $T-$ and $CDB⁺ T$ cells in four non-leukemic controls. Examined using the 828 Kruskal-Wallis test followed by Dunn's multiple comparisons test. In case of multiple p-829 values, the upper one is associated with the Kruskal-Wallis test, while the lower one(s) 830 reflects the result of Dunn's multiple comparison test. (D-E) Correlation plot between the 831 normalized number of $CD3⁺$ (D) and $CD8⁺$ (E) T cells and leukemic blasts in the bone 832 marrow (blast % available for 65 cases), calculated using Spearman correlation. (F-G) 833 Comparison of the normalized abundance of $CD3⁺$ (F) and $CD8⁺$ (G) T cells in the bone 834 marrow across AML differentiation stages (FAB-classifications; Kruskal-Wallis followed by

835 Dunn's multiple comparisons test). Data are presented as mean plus range. The dashed 836 lines indicate the median T- and $CDB⁺ T$ cell abundance in non-leukemic controls. (H-I) 837 Comparison of the estimated abundance of T- (H) and CD8⁺ (I) T cells in the bone marrow of 838 TARGET-AML cases across AML differentiation stages (FAB-classifications; Kruskal-Wallis 839 followed by Dunn's multiple comparisons test). Data are presented as mean plus range. The 840 dashed lines indicate the estimated median $T-$ and $CDB⁺ T$ cell abundance in non-leukemic 841 controls. (J-K) Correlation plot between the estimated number of T- (J) and CD8⁺ (K) T cells 842 and leukemic blasts in the bone marrow (blast % available for 154 cases) of TARGET-AML 843 cases, calculated using Spearman correlation.

844 **Supplementary Figure 2. Overall survival and M2-like macrophage abundance in** 845 **immune-infiltrated and immune-depleted cases across two cohorts.**

846 (A-B) Overall survival between immune-infiltrated and immune-depleted pediatric AML cases 847 in our primary study cohort (A) and in the TARGET-AML cohort (B). (C-D) Correlation plots 848 of the correlation between the M2-predominance score and the normalized (C; our cohort) or 849 estimated (D; TARGET-AML cohort) abundance of CD8⁺ T cells, calculated using Spearman 850 correlation.

851 **Supplementary Figure 3. Representative images of bone marrow biopsies of immune-**852 **infiltrated and immune-depleted pediatric AML, and a non-leukemic control.**

 $(4-B)$ Representative images of CD3⁺ T cells in the bone marrow of immune-depleted cases. 854 (C-D) Representative images of large T cell networks (C) that colocalized with a dense 855 network of B cells (lymphoid aggregates) (D). (E) Representative image of $CD3⁺$ T cell 856 infiltration in the bone marrow of a non-leukemic control.

857 **Supplementary Figure 4. Immune aggregates in the bone marrow of adult AML cases** 858 **treated with ipilimumab-based treatment.** (A) Schematic overview of adult AML cases that 859 were treated with ipilimumab and decitabine, the used techniques, and the examined 860 variables. The table indicates the patient IDs, whether patients responded (yes=green, 861 purple=no) to these therapies, whether the patients had primary AML (AML) or secondary 862 AML (sAML), and whether they were treated in the treatment-naïve or post-stem cell 863 transplantation (SCT) setting. (B-D) Representative multiplex immunofluorescence images of 864 lymphoid aggregates (B-C) and large T cell-dominant networks with sparse B cells (D). (E-J) 865 Longitudinal overview of lymphoid aggregates, T cell-dominant networks, and AML blasts in 866 bone marrow biopsies before treatment according to the clinical trial (baseline), at time of 867 best response, or at end of treatment (EOT). Presented blast percentages are the average 868 of the aspirate and biopsy blast percentages. EC=end of course; the number (e.g., EC1) 869 indicates which course was given (e.g., EC1 indicates that the biopsy was taken after course

870 1). Green IDs indicate responders, purple IDs indicate non-responders. The AML blast 871 percentage was the average of the percentages in the aspirate and the core biopsy. 872 CR=complete morphologic remission with or without complete count recovery and no signs 873 of leukemia elsewhere. *AML1003 had an aplastic bone marrow without hematologic 874 recovery, and AML1011 had 5% blasts by histology.

875 **Supplementary Figure 5. Composition of lymphoid aggregates in immune-infiltrated** 876 **pediatric AML.** (A) Representative images of the region of interest (ROI) selection on the 877 GeoMx Digital Spatial Profiling platform. On the left, both the CD3 (T cell) and CD20 (B cell) 878 stains are shown (DAB, both in brown). On the right, magnifications of immune-aggregate 879 regions (above) and mixed regions (below) are shown. Selection of ROIs was further aided 880 by overlaying stains of CD34 and CD117 (Supplementary Methods). (B) Comparison of the 881 expression of the '12chem' signatures across different region types (Kruskal-Wallis followed 882 by Dunn's multiple comparisons test). (C) Proportions of CD4⁺ and CD8⁺ T cells in lymphoid 883 aggregate (LA), mixed, and control regions. (D-H) Deconvoluted absolute abundance of 884 various cell subsets across several region types (Kruskal-Wallis followed by Dunn's multiple 885 comparisons test). In case of multiple p-values, the upper one is associated with the Kruskal-886 Wallis test, while the lower one(s) reflects the result of Dunn's multiple comparison test.

887 **Supplementary Figure 6. Upregulated genes and the presence of regulatory T cells in** 888 **lymphoid aggregates in immune-infiltrated pediatric AML.** (A) Volcano plot of genes 889 differentially expressed in lymphoid aggregates compared to MIXED1 regions, generated 890 using linear mixed-effect modelling. FC: fold change. (B) Representative images of putative 891 Tregs (CD3⁺FOXP3⁺) in lymphoid aggregates (CD3⁺ T cells). The image on the right reflects 892 a zoom of the region in the green box in the left image. The names below the images reflect 893 the antibodies and the associated colors in the images. (C) Proportion of putative Tregs 894 \equiv among all CD3⁺ T cells in lymphoid aggregates (LA).

895

- 897
- 898
- 899
- 900
- 901

902

Lymphoid aggregate

≥ 100 T cells in direct contact with a dense network of B cells

CD3 CD20

Lymphoid aggregate regions (LA) Mixed regions in aggregate-rich biopsy (MIXED1) aggregates (MIXED2)

Mixed regions in biopsy without

Control regions in non-leukemic control biopsy (CONTROL)

Supplementary Figure 2

CD3 CD20

CD3

• Large T cell-dominant networks with sparse B cells • AML blasts Lymphoid aggregates \bullet

CD3 250 yr \Box SYTO13 \Box CD3 \Box CD45 250 µr

CD20

0-1-1-00

 250 $\frac{\text{<0.001}}{\text{<0.001}}$

A

 $\begin{array}{c} 6 \ 5 \ 6 \ 7 \ \end{array}$

Log2(FC)

